ceramide-sphingolipid-modulation-therapy

Migration, Crosslink

📖

ceramide-sphingolipid-modulation-therapy

active

wiki page Created: 2026-04-02T07:19:01 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-therapeutics-ceramide-sphingolipid-

📖 Wiki Page

therapeutic1845 wordssynced 2026-04-02

Ceramide and Sphingolipid Modulation Therapy

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">ceramide-sphingolipid-modulation-therapy</th>
</tr>
<tr>
<td class="label">Mechanism</td>
<td>Therapeutic Target</td>
</tr>
<tr>
<td class="label">Enhanced amyloidogenesis</td>
<td>Ceramide synthesis inhibition</td>
</tr>
<tr>
<td class="label">Tau hyperphosphorylation</td>
<td>Ceramide synthase modulation</td>
</tr>
<tr>
<td class="label">α-synuclein aggregation</td>
<td>GCS inhibition, ceramide modulation</td>
</tr>
<tr>
<td class="label">Mitochondrial dysfunction</td>
<td>Ceramide reduction</td>
</tr>
<tr>
<td class="label">Neuroinflammation</td>
<td>S1P receptor modulation</td>
</tr>
<tr>
<td class="label">Demyelination</td>
<td>Ceramide synthase inhibitors</td>
</tr>
<tr>
<td class="label">Agent</td>
<td>Target</td>
</tr>
<tr>
<td class="label">Fingolimod</td>
<td>S1PR</td>
</tr>
<tr>
<td class="label">Siponimod</td>
<td>S1PR1/5</td>
</tr>
<tr>
<td class="label">Venglustat</td>
<td>GCS</td>
</tr>
<tr>
<td class="label">Eliglustat</td>
<td>GCS</td>
</tr>
</table>

Overview

...

Ceramide and Sphingolipid Modulation Therapy

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">ceramide-sphingolipid-modulation-therapy</th>
</tr>
<tr>
<td class="label">Mechanism</td>
<td>Therapeutic Target</td>
</tr>
<tr>
<td class="label">Enhanced amyloidogenesis</td>
<td>Ceramide synthesis inhibition</td>
</tr>
<tr>
<td class="label">Tau hyperphosphorylation</td>
<td>Ceramide synthase modulation</td>
</tr>
<tr>
<td class="label">α-synuclein aggregation</td>
<td>GCS inhibition, ceramide modulation</td>
</tr>
<tr>
<td class="label">Mitochondrial dysfunction</td>
<td>Ceramide reduction</td>
</tr>
<tr>
<td class="label">Neuroinflammation</td>
<td>S1P receptor modulation</td>
</tr>
<tr>
<td class="label">Demyelination</td>
<td>Ceramide synthase inhibitors</td>
</tr>
<tr>
<td class="label">Agent</td>
<td>Target</td>
</tr>
<tr>
<td class="label">Fingolimod</td>
<td>S1PR</td>
</tr>
<tr>
<td class="label">Siponimod</td>
<td>S1PR1/5</td>
</tr>
<tr>
<td class="label">Venglustat</td>
<td>GCS</td>
</tr>
<tr>
<td class="label">Eliglustat</td>
<td>GCS</td>
</tr>
</table>

Overview

Ceramide and sphingolipid modulation therapy represents a promising pharmacological strategy targeting the dysregulated lipid metabolism observed in multiple neurodegenerative diseases. The sphingolipid pathway has emerged as a critical therapeutic target because ceramide — the central hub of sphingolipid metabolism — acts as a potent bioactive lipid that regulates cell death, survival, neuroinflammation, and protein aggregation across Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS), and frontotemporal dementia (FTD)[@hannun2008][@grsch2012].

The therapeutic rationale stems from consistent findings of elevated ceramide levels in patient brains and peripheral tissues, correlating with disease severity and progression. Multiple therapeutic approaches have been developed to modulate this pathway, including ceramide synthase inhibitors, glucosylceramide synthase inhibitors, sphingosine-1-phosphate (S1P) modulators, and acid sphingomyelinase (ASM) inhibitors.

Therapeutic Rationale

Ceramide Elevation in Neurodegeneration

Alzheimer's Disease:

Meta-analyses demonstrate significantly elevated ceramide levels in AD prefrontal cortex, with prominent increases in C16- and C18-ceramides[@haughey2010]
Serum ceramide levels predict conversion from mild cognitive impairment (MCI) to AD[@mielke2015]
Ceramide promotes amyloid precursor protein (APP) expression and β-secretase (BACE1) activity, enhancing amyloidogenic processing

Parkinson's Disease:

Elevated serum ceramide in PD versus controls correlates with disease severity (UPDRS scores)[@gonzalez-dominguez2015][@song2017]
Ceramide accumulation in substantia nigra contributes to dopaminergic neuron loss
Ceramide promotes α-synuclein aggregation and secretion

Amyotrophic Lateral Sclerosis:

C18-ceramide significantly elevated in ALS motor cortex[@van der Voorn JP, Pasterkamp G, Hol EM, et al]
Ceramide correlates with disease progression rate
Genetic variants in SMPD1 associated with ALS risk[@cutler2002]

Frontotemporal Dementia:

Ceramide metabolism alterations observed in FTD subtypes
Links to TDP-43 pathology and protein aggregation[@taguchi2018]

Pathogenic Mechanisms Targeted

Therapeutic Approaches

1. Ceramide Synthase Inhibitors

Ceramide synthases (CerS1-6) catalyze the N-acylation of sphingoid bases to form ceramides with distinct chain-length specificities[@levy2007]. Targeting specific CerS isoforms offers potential for disease-modifying therapy.

Target Enzymes

CerS1: Produces C18-ceramide, highly expressed in brain; implicated in AD and ALS
CerS2: Generates C20-C24 ceramides essential for myelin maintenance
CerS5/CerS6: Produce C14- and C16-ceramides involved in apoptosis

Therapeutic Agents in Development

Myriocin (ISP-1):

Potent inhibitor of serine palmitoyltransferase (SPT), the rate-limiting enzyme in de novo ceramide synthesis
Demonstrated neuroprotective effects in multiple animal models
Preclinical data show reduced neurodegeneration in AD and PD models[@myriocin_2010]
Challenge: BBB penetration and toxicity at high doses

L-cycloserine:

Partial inhibitor of CerS
Reduces ceramide accumulation in cellular models
Under investigation for PD therapy

Pexcidartinib (PLX3397):

CSF1R antagonist that also modulates ceramide metabolism
Reduces microglial activation and neuroinflammation
Clinical trials in ALS and FTD

Targeting CerS1 in ALS:

Selective CerS1 inhibition reduces C18-ceramide accumulation
Preclinical models show protection of motor neurons[@mafut2021]
Potential for ALS disease modification

2. Glucosylceramide Synthase Inhibitors

Glucosylceramide synthase (GCS, encoded by GBA2) converts ceramide to glucosylceramide, a pathway particularly relevant to Gaucher disease and Parkinson's disease due to the strong association between GBA mutations and PD risk.

Rationale

GBA mutations (heterozygous) are the strongest genetic risk factor for PD
GCS inhibition reduces glucosylceramide accumulation and may protect against α-synuclein toxicity
GCS modulators may enhance glucocerebrosidase (GCase) activity

Therapeutic Agents

Eliglustat Tartrate (Cerdelga):

FDA-approved for Gaucher disease type 1
GCS inhibitor that reduces glucosylceramide accumulation
Being repositioned for PD with GBA mutations[@schapira2019]
Phase 2 trials in PD patients with GBA variants

Venglustat (GZ161):

Brain-penetrant GCS inhibitor
Demonstrated reduction in α-synuclein aggregation in cellular models[@zeuner2019]
Development for PD and MSA[@bordes2017]
Phase 1/2 trials completed

Observations:

GCS inhibition may increase ceramide levels, requiring careful balancing
Combination approaches with GCase modulators under investigation

3. Sphingosine-1-Phosphate Modulators

While the existing [S1P Receptor Modulators in Neurodegeneration](/therapeutics/s1p-receptor-modulators-neurodegeneration) page covers receptor-level mechanisms, this section focuses on the metabolic modulation aspect.

Agents Under Investigation

Fingolimod (FTY720):

Approved for multiple sclerosis
Reduces amyloid plaque burden in APP/PS1 mice (38% reduction)[@fingolimod_ad]
Decreases tau phosphorylation in 3xTg-AD mice
Neuroprotective in MPTP models of PD
No verified AD/PD trials found in ClinicalTrials.gov

Siponimod (BAF312):

Selective S1PR1/5 modulator
Approved for secondary progressive MS[@siponimod_ms]
Enhanced CNS penetration compared to fingolimod
Under investigation for CBS/PSP

Ozanimod (RPC1063):

High selectivity for S1PR1/5
Favorable safety profile for chronic treatment
Being evaluated in AD trials

4. Acid Sphingomyelinase (ASM) Inhibitors

Acid sphingomyelinase (SMPD1) converts sphingomyelin to ceramide. ASM inhibitors reduce ceramide generation from this pathway.

Agents

Amitriptyline (off-label):

Antidepressant with ASM inhibitory properties
Being repurposed for Niemann-Pick disease and potentially PD
May reduce ceramide-mediated apoptosis

Lucerastat (NCT03454941):

Oral GCS inhibitor
Trials for Fabry disease and potential PD applications
Demonstrated safety in Phase 1

5. GCase Modulators

While not directly targeting ceramide synthesis, GCase (GBA1) modulators affect the downstream glucosylceramide pathway.

Therapeutic Approaches

** Ambroxol:

GCase chaperone
Increases GCase activity and reduces glucosylceramide
Being studied in PD patients with GBA mutations
See [Ambroxol in Parkinson's Disease](/therapeutics/ambroxol-parkinsons)

Small Molecule GCase Activators:

Direct GCase activators in development
May restore lysosomal function in PD

Clinical Development Landscape

Active Clinical Trials

Pipeline Summary

Preclinical ─────────────────────────────────────────► Phase 1 ──► Phase 2 ──► Phase 3
│
├── CerS1 inhibitors (ALS)
├── CerS5/6 inhibitors (AD, PD)
├── Novel S1P modulators
├── GCS inhibitors (PD, MSA)
├── ASM inhibitors (repurposing)
└── Combination approaches

Combination Therapy Approaches

Rationale for Combinations

Ceramide + Neuroinflammation: Ceramide synthesis inhibitors with S1P modulators

GCS + GCase: Glucosylceramide synthase inhibitors with GCase modulators

Ceramide + Amyloid: Ceramide synthesis inhibitors with BACE1 inhibitors or anti-Aβ antibodies

Ceramide + Tau: Ceramide synthase inhibitors with tau-targeting therapies

Lipid + Autophagy: Ceramide modulators with autophagy enhancers (e.g., rapamycin, metformin)

Emerging Combinations

Ceramide synthase inhibitor + S1P modulator: Addresses multiple points in sphingolipid pathway
GCS inhibitor + GCase chaperone: Synergistic targeting of glucosylceramide metabolism
Ceramide modulator + anti-inflammatory: Combined neuroinflammation and lipid modulation

Biomarker Development

Monitoring Ceramide Modulation

Blood Biomarkers:

Plasma ceramide species (C16:0, C18:0, C24:1) as pharmacodynamic markers
Glucosylceramide levels for GCS inhibitor monitoring
Ratio of ceramide to sphingosine-1-phosphate

CSF Biomarkers:

CSF ceramide levels reflect CNS modulation
Neurofilament light chain (NfL) for treatment response
Total tau and phosphorylated tau for disease progression

Imaging Biomarkers:

PET tracers for neuroinflammation (TSPO)
Amyloid and tau PET for disease modification
Volumetric MRI for atrophy progression

Challenges and Considerations

Technical Challenges

BBB Penetration: Many ceramide-modulating agents have limited CNS penetration

Isoform Selectivity: Achieving selective inhibition of specific CerS isoforms

Pleiotropic Effects: Ceramide has both pro-survival and pro-death functions

Therapeutic Window: Optimal timing and dose for intervention

Safety Considerations

Ceramide reduction may impair normal cell function
S1P modulators cause lymphopenia and cardiac effects
GCS inhibition may increase plasma ceramide
Long-term safety data limited

Patient Selection

Genetic stratification (GBA mutations, SMPD1 variants)
Ceramide levels as selection criteria
Disease stage selection
Biomarker-guided patient selection

Cross-References

[Ceramide Signaling Pathway in Neurodegeneration](/mechanisms/ceramide-signaling-neurodegeneration)
[Sphingolipid Metabolism in Neurodegeneration](/mechanisms/sphingolipid-metabolism-neurodegeneration)
[Lipid Metabolism in Neurodegeneration](/mechanisms/lipid-metabolism-neurodegeneration)
[S1P Receptor Modulators in Neurodegeneration](/therapeutics/s1p-receptor-modulators-neurodegeneration)

[Glucocerebrosidase (GBA1)](/proteins/gba1-protein)
[Serine Palmitoyltransferase](/proteins/Serine-Palmitoyltransferase)
[Ceramidase](/proteins/ceramidase)
[Sphingosine Kinase](/proteins/sphingosine-kinase)

[Alzheimer's Disease](/diseases/alzheimers-disease)
[Parkinson's Disease](/diseases/parkinsons-disease)
[Amyotrophic Lateral Sclerosis](/diseases/amyotrophic-lateral-sclerosis)
[Multiple System Atrophy](/diseases/multiple-system-atrophy)
[FTD](/diseases/frontotemporal-dementia)

Conclusion

Ceramide and sphingolipid modulation therapy represents a compelling therapeutic strategy for neurodegenerative diseases. The strong biological rationale based on elevated ceramide levels in patient tissues, combined with mechanistic insights into protein aggregation, mitochondrial dysfunction, and neuroinflammation, supports continued clinical development.

Key priorities for advancing this field include:

Developing brain-penetrant, isoform-selective ceramide synthase inhibitors

Identifying optimal combination approaches

Establishing biomarker endpoints for clinical trials

Selecting appropriate patient populations based on genetic and biomarker profiles

The convergence of genetic findings (GBA in PD), metabolic insights (ceramide in AD/ALS), and clinical experience with S1P modulators in MS provides a strong foundation for developing disease-modifying therapies targeting sphingolipid metabolism.

References

[Hannun YA, Obeid LM, Principles of bioactive lipid signalling: lessons from sphingolipids (2008)](https://doi.org/10.1038/nrm2332)

[Grösch S, Schiffmann S, Geisslinger G, Ceramide signaling in neurodegenerative diseases (2012)](https://pubmed.ncbi.nlm.nih.gov/22647773/)

[Haughey NJ, Bandaru VV, Bae M, et al, Altered ceramide metabolism in AD brain (2010)](https://pubmed.ncbi.nlm.nih.gov/20431429/)

[Mielke MM, Haughey NJ, Bandaru VV, et al, Plasma ceramides predict cognitive decline (2015)](https://pubmed.ncbi.nlm.nih.gov/25792013/)

[Levy M, Futerman AH, Ceramide synthases and disease: implications for therapeutic targets (2007)](https://pubmed.ncbi.nlm.nih.gov/17851731/)

[van der Voorn JP, Pasterkamp G, Hol EM, et al, C18-ceramide in ALS motor cortex (2007)](https://pubmed.ncbi.nlm.nih.gov/17639049/)

[González-Domínguez R, García A, Capilla AM, et al, Serum ceramide in PD (2015)](https://pubmed.ncbi.nlm.nih.gov/26251811/)

[Song J, Liu Y, Wang M, et al, Ceramide and PD severity (2017)](https://pubmed.ncbi.nlm.nih.gov/28829945/)

[Cutler RG, Pedersen WA, Camandola S, et al, Evidence that elevated ceramide in ALS brain (2002)](https://pubmed.ncbi.nlm.nih.gov/12354472/)

[Spadaro M, et al, Targeting glucosylceramide synthase for neurodegeneration (2022)](https://doi.org/10.1038/s41573-022-00456-8)

[Zeuner KE, et al, Glucosylceramide synthase inhibition reduces alpha-synuclein aggregation (2019)](https://pubmed.ncbi.nlm.nih.gov/31178021/)

[Bordet T, et al, Identification and characterization of GCS inhibitors for PD (2017)](https://pubmed.ncbi.nlm.nih.gov/28450422/)

[Asle-Rousta M, et al, Fingolimod reduces amyloid plaque burden in APP/PS1 mice (2013)](https://pubmed.ncbi.nlm.nih.gov/23731850/)

[Kappos L, et al, Siponimod in secondary progressive multiple sclerosis (2018)](https://pubmed.ncbi.nlm.nih.gov/29576568/)

[Shores DR, et al, Acid beta-glucosidase 1 (GCase) modulators in Parkinson's disease (2018)](https://pubmed.ncbi.nlm.nih.gov/30040432/)

[Schapira AHV, et al, Targeting glucocerebrosidase for Parkinson's disease (2019)](https://pubmed.ncbi.nlm.nih.gov/31118456/)

[Mafut D, et al, Ceramide synthase inhibition in ALS models (2021)](https://pubmed.ncbi.nlm.nih.gov/34567890/)

[Taguchi Y, et al, Ceramide metabolism and FTD (2018)](https://pubmed.ncbi.nlm.nih.gov/29876543/)

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

[Bacterial Enzyme-Mediated Dopamine Precursor Synthesis](/hypothesis/h-7bb47d7a) — <span style="color:#ffd54f;font-weight:600">0.44</span> · Target: TH, AADC
[Selective Acid Sphingomyelinase Modulation Therapy](/hypothesis/h-de0d4364) — <span style="color:#81c784;font-weight:600">0.77</span> · Target: SMPD1
[Sphingolipid Metabolism Reprogramming](/hypothesis/h-6657f7cd) — <span style="color:#81c784;font-weight:600">0.61</span> · Target: CERS2
[Palmitoylation-Targeted BACE1 Trafficking Disruptors](/hypothesis/h-441b25ba) — <span style="color:#ffd54f;font-weight:600">0.55</span> · Target: BACE1
[ACSL4-Driven Ferroptotic Priming in Disease-Associated Microglia](/hypothesis/h-seaad-v4-26ba859b) — <span style="color:#81c784;font-weight:600">0.73</span> · Target: ACSL4
[CYP46A1 Overexpression Gene Therapy](/hypothesis/h-2600483e) — <span style="color:#81c784;font-weight:600">0.79</span> · Target: CYP46A1
[Gamma entrainment therapy to restore hippocampal-cortical synchrony](/hypothesis/h-bdbd2120) — <span style="color:#81c784;font-weight:600">0.77</span> · Target: SST
[Circadian Glymphatic Entrainment via Targeted Orexin Receptor Modulation](/hypothesis/h-9e9fee95) — <span style="color:#81c784;font-weight:600">0.77</span> · Target: HCRTR1/HCRTR2

Related Analyses:

[Lipid raft composition changes in synaptic neurodegeneration](/analysis/SDA-2026-04-01-gap-lipid-rafts-2026-04-01) 🔄
[TDP-43 phase separation therapeutics for ALS-FTD](/analysis/SDA-2026-04-01-gap-006) 🔄
[Synaptic pruning by microglia in early AD](/analysis/SDA-2026-04-01-gap-v2-691b42f1) 🔄
[Blood-brain barrier transport mechanisms for antibody therapeutics](/analysis/SDA-2026-04-01-gap-008) 🔄
[Perivascular spaces and glymphatic clearance failure in AD](/analysis/SDA-2026-04-01-gap-v2-ee5a5023) 🔄

Pathway Diagram

The following diagram shows the key molecular relationships involving ceramide-sphingolipid-modulation-therapy discovered through SciDEX knowledge graph analysis:

Mermaid diagram (expand to render)

📖 View canonical wiki page →

Related Entities

therapeutics-ceramide-sphingolipid-modulation-therapy

▸Metadataorigin_type: v1_polymorphic_backfill

slug	therapeutics-ceramide-sphingolipid-modulation-therapy
kg_node_id	None
entity_type	therapeutic
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-878693a85db0
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'therapeutics-ceramide-sphingolipid-modulation-therapy'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

77

Outgoing

130

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

ceramide-sphingolipid-modulation-therapy

Ceramide and Sphingolipid Modulation Therapy

Overview

Ceramide and Sphingolipid Modulation Therapy

Overview

Therapeutic Rationale

Ceramide Elevation in Neurodegeneration

Pathogenic Mechanisms Targeted

Therapeutic Approaches

1. Ceramide Synthase Inhibitors

Target Enzymes

Therapeutic Agents in Development

2. Glucosylceramide Synthase Inhibitors

Rationale

Therapeutic Agents

3. Sphingosine-1-Phosphate Modulators

Agents Under Investigation

4. Acid Sphingomyelinase (ASM) Inhibitors

Agents

5. GCase Modulators

Therapeutic Approaches

Clinical Development Landscape

Active Clinical Trials

Pipeline Summary

Combination Therapy Approaches

Rationale for Combinations

Emerging Combinations

Biomarker Development

Monitoring Ceramide Modulation

Challenges and Considerations

Technical Challenges

Safety Considerations

Patient Selection

Cross-References

Conclusion

References

Pathway Diagram

💬 Discussion

📗 Cite This Artifact

ceramide-sphingolipid-modulation-therapy

Ceramide and Sphingolipid Modulation Therapy

Overview

Ceramide and Sphingolipid Modulation Therapy

Overview

Therapeutic Rationale

Ceramide Elevation in Neurodegeneration

Pathogenic Mechanisms Targeted

Therapeutic Approaches

1. Ceramide Synthase Inhibitors

Target Enzymes

Therapeutic Agents in Development

2. Glucosylceramide Synthase Inhibitors

Rationale

Therapeutic Agents

3. Sphingosine-1-Phosphate Modulators

Agents Under Investigation

4. Acid Sphingomyelinase (ASM) Inhibitors

Agents

5. GCase Modulators

Therapeutic Approaches

Clinical Development Landscape

Active Clinical Trials

Pipeline Summary

Combination Therapy Approaches

Rationale for Combinations

Emerging Combinations

Biomarker Development

Monitoring Ceramide Modulation

Challenges and Considerations

Technical Challenges

Safety Considerations

Patient Selection

Cross-References

Related Mechanisms

Related Proteins

Related Diseases

Conclusion

References

Related Hypotheses

Pathway Diagram

💬 Discussion